Haleon to invest $87 million in Shanghai oral health plant to expand China presence

Core Insights - Haleon PLC is investing £65 million ($87.2 million) in a new oral health plant in Shanghai to enhance its growth in markets like China and India [1] - The company aims to deepen its portfolio through bolt-on mergers and acquisitions, as stated by CEO Brian McNamara [1] E-commerce and Market Strategy - E-commerce constitutes approximately 40% of Haleon's business in China and is crucial for the company's expansion in this key market [2] - The company has taken full control of its joint venture with Tianjin TSKF Pharmaceutical Co. to sell over-the-counter drugs in China [2] Financial Performance and Resilience - Haleon, formed from GSK Plc and Pfizer Inc. in 2022, experienced a decline in share prices after reporting weaker-than-expected sales due to a mild cold and flu season [3] - Core product categories, including Sensodyne toothpaste and Advil painkillers, have shown resilience despite inflationary pressures [4] - The company has not faced issues related to comments from US President Donald Trump linking paracetamol to autism [4]